Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Antifungal Resistance in Patients with Candidemia: A Retrospective Cohort Study

View through CrossRef
Abstract Background: Candidaemia is the most common form of invasive candidiasis. Resistant Candida blood stream infection (BSI) is rising, with limitations on the development of broader-spectrum antifungal agents worldwide. Our study aimed to identify the rate of antifungal-resistant candidaemia and the distribution of these species, determine the risk factors associated with antifungal resistance and evaluate the association of antifungal-resistant candidaemia with the length of intensive care unit (ICU) and hospital stay and with 30-day mortality. Methods: A retrospective cohort study was conducted at King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia. Adult patients diagnosed with candidaemia from January 2006 to December 2017 were included. Results: A total of 196 BSIs were identified in 94 males (49.74%) and 95 females (50.26%). C. glabrata was the most commonly isolated Candida species, with 59 (30%), followed by C. albicans with 46 (23%). Susceptibility data were available for 122/189 patients, of whom 26/122 (21%) were resistant to one or more antifungals. C. parapsilosis with available sensitivity data were found in 30/122 isolates, of which 10/30 (33%) were resistant to fluconazole. Risk factors significantly associated with antifungal-resistant candidaemia included previous echinocandin exposure (odds ratio (OR) =1.38; 95% confidence interval (CI) (1.02-1.85); P= 0.006) and invasive ventilation (OR=1.3; 95% CI (1.08-1.57); P= 0.005). The median length of ICU stay was 29 days [range 12-49 days] in the antifungal-resistant group and 18 days [range 6.7-37.5 days] in the antifungal-sensitive group. The median length of hospital stay was 51 days [range 21-138 days] in the antifungal-resistant group and 35 days [range 17-77 days] in the antifungal-sensitive group. Thirty-day mortality was 15 (57.7%) and 54 (56.25%) among the antifungal-resistant and antifungal-sensitive groups, respectively (OR=1.01; 95% CI (0.84-1.21); P= 0.89).Conclusions: Our results indicate an increase in the rate of non-C. albicans candidaemia. The rise in C. parapsilosis resistance to fluconazole is alarming. Further studies are required to confirm this finding
Title: Antifungal Resistance in Patients with Candidemia: A Retrospective Cohort Study
Description:
Abstract Background: Candidaemia is the most common form of invasive candidiasis.
Resistant Candida blood stream infection (BSI) is rising, with limitations on the development of broader-spectrum antifungal agents worldwide.
Our study aimed to identify the rate of antifungal-resistant candidaemia and the distribution of these species, determine the risk factors associated with antifungal resistance and evaluate the association of antifungal-resistant candidaemia with the length of intensive care unit (ICU) and hospital stay and with 30-day mortality.
Methods: A retrospective cohort study was conducted at King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.
Adult patients diagnosed with candidaemia from January 2006 to December 2017 were included.
Results: A total of 196 BSIs were identified in 94 males (49.
74%) and 95 females (50.
26%).
C.
glabrata was the most commonly isolated Candida species, with 59 (30%), followed by C.
albicans with 46 (23%).
Susceptibility data were available for 122/189 patients, of whom 26/122 (21%) were resistant to one or more antifungals.
C.
parapsilosis with available sensitivity data were found in 30/122 isolates, of which 10/30 (33%) were resistant to fluconazole.
Risk factors significantly associated with antifungal-resistant candidaemia included previous echinocandin exposure (odds ratio (OR) =1.
38; 95% confidence interval (CI) (1.
02-1.
85); P= 0.
006) and invasive ventilation (OR=1.
3; 95% CI (1.
08-1.
57); P= 0.
005).
The median length of ICU stay was 29 days [range 12-49 days] in the antifungal-resistant group and 18 days [range 6.
7-37.
5 days] in the antifungal-sensitive group.
The median length of hospital stay was 51 days [range 21-138 days] in the antifungal-resistant group and 35 days [range 17-77 days] in the antifungal-sensitive group.
Thirty-day mortality was 15 (57.
7%) and 54 (56.
25%) among the antifungal-resistant and antifungal-sensitive groups, respectively (OR=1.
01; 95% CI (0.
84-1.
21); P= 0.
89).
Conclusions: Our results indicate an increase in the rate of non-C.
albicans candidaemia.
The rise in C.
parapsilosis resistance to fluconazole is alarming.
Further studies are required to confirm this finding.

Related Results

Antifungal Resistance in Patients with Candidemia: A Retrospective Cohort Study
Antifungal Resistance in Patients with Candidemia: A Retrospective Cohort Study
Abstract Background Candidemia is the most common form of invasive candidiasis. Resistant Candida blood stream infection (BSI) is rising with limitation in the development...
Incidence and risk factors for COVID‐19 associated candidemia (CAC) in ICU patients
Incidence and risk factors for COVID‐19 associated candidemia (CAC) in ICU patients
AbstractBackgroundCritically ill COVID‐19 patients have a high risk for the development of candidemia due to being exposed to both well‐defined classical risk factors and COVID‐19‐...
P-1727. Defining Uncomplicated Candidemia suitable for “shorter is better” Treatment
P-1727. Defining Uncomplicated Candidemia suitable for “shorter is better” Treatment
Abstract Background The success of candidemia treatment depends on patient baseline characteristics, as well as clinical ...
Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes
Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes
A retrospective study of 76 episodes of candidemia in 73 patients with underlying hematological malignancy, from 1988 until 1997, has been conducted to evaluate the clinical charac...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract Introduction Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Epidemiology and Risk Factors for Antifungal Resistance in Patients with Candidemia
Epidemiology and Risk Factors for Antifungal Resistance in Patients with Candidemia
Abstract Background Candida is a common nosocomial blood pathogen associated with high mortality. Data on antifungal resistance ...

Back to Top